Canine Immuno Platform Vetigenics possesses a unique canine-centric phage display library with over 40 billion independent scFv members, enabling rapid isolation and engineering of canine-focused immunotherapeutics that can be developed into full-length IgGs, BiTEs, and CAR-T constructs for dogs and potentially cats.

CANIBODIES Advantage The CANIBODIES immunomodulators are derived from native canine germline genes, reducing immunogenicity and eliminating the need for canineization or mouse components, presenting a compelling value proposition for premium veterinary oncology and immunotherapy markets.

Strategic Collaboration Strong academic and industry ties, including UPenn founders and a broad expert network in animal and human health, open partnership opportunities for co-development, clinical validation, and access to broader distribution channels in veterinary oncology and infectious disease areas.

Financing & Growth Recent seed funding of six million dollars signals investor confidence and potential for accelerated GMP-ready development, enabling targeted sales efforts to veterinary clinics, universities, and biotech partners looking for canine-specific biologics.

Market Readiness Existing press coverage and a clear product roadmap for cancer, infections, and immune-mediated diseases position Vetigenics to pursue early pilot programs with high-value veterinary centers and animal health distributors seeking innovative immunotherapies.